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deviate from practice guidelines. We compared observed clinical testing and treat-
ment practices to practices that follow guidelines to target adjuvant trastuzumab 
in HER2+ BC using cost-utility analysis. Methods: We used a probabilistic decision 
tree linked to a Markov model to estimate the incremental cost-utility of 2 alterna-
tive test-treat strategies to target adjuvant trastuzumab in Canadian BC patients; 
primary fluorescence in situ hybridization (FISH) vs. primary immunohistochem-
istry (IHC) with FISH confirmation with trastuzumab treatment for all FISH+ or 
IHC+. The BC Markov model was calibrated against Canadian BC registry mortality. 
Population-level observational data informed model probabilities of confirmatory 
FISH testing, probabilities of treatment based on test results, and HER2+ disease 
prevalence under the current practice scenario. Uncertainty was characterized 
using deterministic and probabilistic sensitivity analyses and cost-effectiveness 
acceptability curves (CEACs). Results: In the base case analysis assuming 20% 
HER2+ disease prevalence and perfect adherence to testing and treatment guide-
lines, primary FISH testing was dominant; it decreased costs by a mean of $815 and 
improved outcomes by 0.0022 QALYS compared to the strategy of primary IHC with 
FISH confirmation of equivocal results. Health outcomes were poorer in simula-
tions of current testing and treatment practice. Results were sensitive to HER2+ 
disease prevalence rate, test accuracy, treatment benefit carryover and testing 
behaviors. ConClusions: Improved adherence to treatment guidelines combined 
with primary FISH testing could improve long-term outcomes and costs in practice. 
Local disease epidemiology should be considered when formulating personalized 
medicine policies. Scenario analyis comparisons of guideline adherent vs. practice 
patterns derived from observational data can provide important insights into the 
consequences of deviations from practice when forming policy.
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objeCtives: This research aimed to estimate the standard of resource use 
and its cost associated of treating CML patients, considering hematological 
and non-hematological adverse events grades 3-4 from the perspective of the 
Brazilian National Health System. Cost of treatment per event was generated 
as a result. Methods: A Delphi methodology was applied in Brazil to study the 
management of adverse events related to CML by collecting data on resource 
used and estimating costs associated. Ten experts completed the questionnaires 
developed and the results were compiled and validated. The data collected were 
related to the percentage of patients affected by each AE and to the resource 
used for management. The unit cost of resources was based on the Price Bank 
System (SUS-SIGTAP). Cost of treatment considered treatment options and moni-
toring (e.g., outpatient visits, laboratory tests, procedures, hospitalizations) in 
the Brazilian Public Health System. Results: Among non-hematologic adverse 
events, gastrointestinal bleeding and central nervous system (CNS) hemorrhage 
presented the highest costs of treatment (R$ 1.022,90 and R$ 1.173,34, respectively). 
Hospitalization was the resource with more impact; mainly in CNS hemorrhage, 
with an average length of hospitalization reported by the experts of 1 week and 
also demanded by 100% of patients affected by this AE. Management of cardiac 
events and pericardial effusion was R$973,35 and R$3.896,55. Cytopenias are the 
most commonly events in patients with CML receiving BCR–ABL inhibitors; experts 
suggested use of growth factors in patients with CML receiving TKI therapy. Costs 
associated with the management of hematologic adverse events are: Anemia: 
R$14,93, Thrombocytopenia: R$14,47 and neutropenia: R$211,54. ConClusions: 
Adverse event management in CML patients has important economic impact All 
adverse events related to treatment of CML, with differences in the occurrence 
and intensity should be valued and recorded as contributing to the estimative of 
total cost of treating the disease.
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objeCtives: Examine health care cost and utilization among patients diagnosed 
with metastatic colorectal cancer (mCRC) or Gastrointestinal stromal tumor (GIST) 
prior to being treated with Stivarga® (regorafenib). Methods: Adult patients 
treated with Stivarga from 9/27/12-7/31/13 were identified from a large national US 
claims database. Patients were retained if they were continuously enrolled in the 
health plan for at least 6 months before the initial (index) diagnosis and 1 month 
after the index diagnosis. Patients were required to be diagnosed with mCRC or GIST, 
be 18+ years old, and have non-missing demographic information. Health care cost 
and utilization was examined during 2 time periods; 1) the 6 months immediately 
preceding the index fill (fixed baseline) and 2) the entire variable length period pre-
ceding the index fill (variable baseline). Cancer-related cost and utilization included 
claims with a diagnosis of cancer. Results: 283 patients were treated with Stivarga 
and 235 met all inclusion criteria. Mean age was 61.6 years, 66.4% were female, and 
38.7% were Medicare Advantage patients. Mean length of baseline enrollment was 
4.2 years (median: 3.3 years). In the 6-month baseline period, 41.3% of patients had 
an ER visit and 34.0% had an inpatient stay (IP); 18.7% and 32.8% had a cancer-related 
ER visit and IP stay, respectively. On average, patients had 35.8 ambulatory visits; 
27.8 were cancer-related. Mean 6-month health care cost was $78,771 ($6,559 phar-
macy, $72,212 medical); the majority of medical costs were cancer-related ($68,866). 
Cancer-related ambulatory services and IP stays accounted for $57,814 and $9,713, 
respectively. In the variable baseline, cancer-related medical costs were $314,410 
with $240,544 in ambulatory costs. The cost of all chemotherapy (oral and adminis-
tered) was $168,386. ConClusions: Patients treated with Stivarga incur significant 
health care cost and utilization, accounting for over $18.5 million in health care cost 
in the 6 months prior to initiating Stivarga.
ally. All costs were reported in Egyptian pounds of the financial year 2013. Results: 
The total quality-adjusted life-years (QALYs) of pazopanib was estimated to be 725 
and that for sunitinib was 674, which resulted in a difference of 51 QALYs. The total 
costs for pazopanib and sunitinib were EGP 2,692,116 and EGP 3,712,660, respectively 
(the difference was -1,020,543), which yielded an incremental cost-effectiveness 
ratio of EGP -19,946/QALY. Thus, pazopanib was superior. Various one-way sensi-
tivity analyses indicated that the overall survival medians of both drugs had the 
greatest effects on the results. ConClusions: The present study concludes that, 
from the perspective of the health insurance, pazopanib is more effective and less 
costly than sunitinib for patients with metastatic renal cell carcinoma. This model 
addresses both the health and economic implications of both drugs. These results 
suggest that pazopanib is the superior therapy. This study helps to inform decisions 
about the allocation of health care system resources and to achieve better health 
in the Egyptian population.
PCN132
Cost-utility aNalysis of Coffee CoNsumPtioN foR PReveNtioN of 
ChRoNiC disease aNd CaNCeR iN the uNited states
O’Day K, Campbell C.M., Popelar B.V.
Xcenda, LLC, Palm Harbor, FL, USA
objeCtives: Coffee (Coffea arabica) is one of the most widely consumed beverages 
worldwide. Epidemiologic studies suggest coffee may prevent some chronic diseases 
and cancers. This study aims to assess the cost-utility of coffee consumption from 
a US consumer perspective. Methods: A cohort life-table analysis was developed 
to model life years (LYs) and quality-adjusted life years (QALYs) of coffee drink-
ers versus non-drinkers over a lifetime horizon. Age- and sex-specific incidence 
and mortality rates were used to model outcomes of chronic disease (Alzheimer’s, 
depression/suicide, diabetes, heart failure, Parkinson’s, stroke) and cancer (blad-
der, breast, colorectal, endometrial, esophageal, leukemia, liver, oral, pancreatic, 
prostate). Relative risks of chronic diseases and cancers by cups of coffee consumed 
daily were obtained from meta-analyses of prospective cohort and case-control 
studies. Utility weights, baseline health care costs, and attributable disease costs 
were obtained from the literature. Costs per cup of coffee were estimated for home 
preparation and obtained from a national sample of low- and high-cost vendors. 
Incremental analyses were conducted by dose, cost, and sex. The model was vali-
dated by comparing predicted life-expectancy to data from studies examining all-
cause mortality of coffee consumption. Probabilistic sensitivity analyses (PSA) were 
conducted. Results: Coffee increased undiscounted LYs in 2, 4, and 6 cup/day male 
(0.29, 0.52, 0.70) and female (0.31, 0.54, 0.69) drinkers, respectively, compared to 
non-drinkers. Home preparation resulted in ICERs per discounted QALY of $36,031, 
$44,125, and $55,572 for male and $31,029, $37,779, and $46,280 for female drink-
ers, respectively, for 2, 4, and 6 cups/day. ICERs were higher for coffee purchased 
from low-cost vendors (> $50,000/QALY) and high-cost vendors (> $80,000/QALY). 
In the PSA, 4 and 6 cups/day were most likely cost-effective for males and females, 
respectively, at a $50,000/QALY threshold. ConClusions: Coffee consumption may 
be a cost-effective approach to improve health outcomes. Given the limitations of 
observational effectiveness data, additional research is warranted.
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objeCtives: Compare demographic and clinical characteristics among colorectal 
cancer (CRC) patients with different treatment lines (TL) in the U.S. veteran popula-
tion. Methods: Adult patients with at least one administration of CRC treatment 
were selected from the U.S. Veterans Health Administration database (01APR2006-
30SEP2012). The first observed treatment date was designated as the index date. 
Patients were required to have continuous pharmacy and medical benefits at least 
6 months pre-index date (baseline) and were followed until the earliest of death, 
or end of enrollment or study period. At least one primary CRC diagnosis code was 
required during the baseline period. Four cohorts were created based on the number 
of TL. Demographic and clinical characteristics were compared among patients with 
one, two, three, or four TL using appropriate statistical tests. Results: A total of 
11,078 patients were included in the study sample (63% with one TL; 22% with two 
TL; 8% with three TL; 7% with four TL). Patients treated with three or four TL were 
similar in age (3 TL: 63.8 years; 4 TL: 63.3) but significantly younger compared to 
patients with one or two lines (1 TL: 67.0; 2 TL: 64.6). Patients with 3 or 4 TL had a 
lower Chronic Disease Score, and lower rates of hypertension and stroke. During the 
6-month baseline period, patients with 1 TL had much longer hospitalization stays 
and a higher rate of inpatient visits (7.3 days, 57.4%) compared to patients in other 
cohorts. A similar trend was found in baseline health care costs, where patients 
with 1 TL incurred the highest costs ($38,010) compared to the other three cohorts 
(2 TL: $34,332; 3 TL: $33,738; 4 TL: $31,120; all p-values< 0.002). ConClusions: CRC 
patients with more than two TL were younger and had less comorbid conditions 
than patients with one or two TL.
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objeCtives: Observational research suggests that personalized medicine practices 
in human epidermal growth factor receptor-2 positive (HER2+) breast cancer (BC) 
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was highest among patients who were using oral chemotherapy agents (34.1%). The 
number of non-adherent behaviors was significantly associated with a decrease 
in functional well-being (FWB; b= -1.40), FACT-G total score (b= -3.01), FACT-B total 
score (b= -3.92), and FACT trial outcome index (FACT-TOI; b= -2.98) (all p< .05). These 
relationships were stronger when focusing on respondents who were using an oral 
chemotherapy agent (n= 44) (bs= -3.14, -7.37, -6.11, -8.63 for FWB, FACT-G, FACT-B, and 
FACT-TOI, respectively). ConClusions: Approximately a third reported engaging 
in non-adherent behavior. These behaviors were associated with significant decre-
ments in health status, suggesting improvements in adherence could correspond 
to quality of life benefits to the patient.
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objeCtives: Utility values used in economic evaluations of new products reflect 
the strength of preference for the health related quality of life (HRQL) of a given 
health state. These can be captured using the time trade-off (TTO) methodology. 
The aim of this study was to elicit societal utility values for states related to chronic 
lymphocytic leukemia (CLL). Methods: Nine health states were developed fol-
lowing a literature review, interviews with patients (n= 6) and clinicians (n= 5), and 
review by lay members of the public (cognitive debriefing; n= 5). These health states 
were: progression free survival (PFS) on initial intravenous (IV) therapy; PFS on ini-
tial oral therapy; PFS on initial therapy with increased hospital visits; PFS without 
therapy; progression after 1st line therapy; PFS on 2nd line therapy; PFS without 2nd 
line therapy (post 2nd line treatment, but not currently receiving therapy); further 
progression (disease progression after 2 lines of treatment); and relapsed lines of 
treatment (≥ 3 lines of treatment). One hundred members of the UK general public 
valued each health state using the TTO methodology. Results: PFS states were 
the least burdensome: PFS without therapy (mean utility= 0.82); PFS on initial oral 
therapy (0.71); PFS on initial IV therapy (0.67), apart from PFS on initial therapy with 
increased hospital visits (0.55). Mean utility for disease progression after 1st line 
therapy was 0.66 and for PFS without 2nd line therapy was 0.71; further progres-
sion (0.59), PFS on 2ndline therapy (0.55), and relapsed lines of treatment (0.42) had 
greater burdens. ConClusions: The results show the weights that the general 
public place on CLL states, underlining the value in maintaining PFS for as long as 
possible. Findings also highlight the extent to which HRQL declines following first 
line progression. These findings can support the estimation of quality adjusted life 
years associated with treatments for CLL.
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objeCtives: Health-state utilities values (HSUVs) are an essential component for 
cost-utility analysis (CUA). The aim of this review was to systematically identify 
utility weights associated with advanced gastric (GC), oesophageal (OC), or gastro-
oesophageal junction (GEJ) adenocarcinoma. Methods: Embase, MEDLINE and 
Cochrane databases (accessed September 2013) were interrogated for relevant 
studies using a predefined search strategy. Studies eligible for inclusion included 
those reporting HSUVs using direct (standard gamble [SG] and time-trade-off 
[TTO]) and indirect methods (such as EuroQol 5D [EQ-5D], short-form 6D [SF-6D] 
and 15D). Results: A total of 703 publications were identified, of which eight met 
the inclusion criteria (GC, n= 2; mixed population [MP], n= 4; OC, n= 2). The most 
commonly used instrument to estimate HSUVs was the EQ-5D (n= 7): post-chem-
otherapy (GC, 0.550 [n= 1]; MP, 0.66-0.76 [n= 1]); progression-free survival (GC, 0.73 
[n= 1]); weight loss (MP, 0.52-0.69 [n= 2]); patient’s valuation of health state (OC, 
0.60-0.93 depending on stage [n= 1]); dysphagia-associated (OC, 0.39-0.82, depending 
on score [n= 1]); societal valuation of health state (OC, 0.15-0.77 [n= 1]); inoperable 
OC/GEJ (MP, 0.63 [n= 1]). One study derived utilities using the SF-6D and the 15D 
(post-chemotherapy in GC patients, 0.606 and 0.685, respectively). In two studies 
the TTO method was used to determine the following HSUVs: patient’s valuation of 
health state (OC, 0.52-0.80 depending on stage [n= 1]); societal valuation of health 
state (0.15-0.77, [n= 1]); dysphagia-associated (OC, 0.25-0.86, depending on score 
[n= 1]); inoperable OC (0.08-0.66, depending on health state [n= 1]). Only one study 
determined HSUVs for inoperable OC according to the SG method (0.08-0.78, depend-
ing on health state). ConClusions: There are limited data estimating HSUVs in 
patients with advanced GC, OC or GEJ. Comparisons are confounded by heteroge-
neity across patient and study characteristics in the identified studies. Further 
research into HSUVs associated with advanced gastric/oesophageal cancers is 
required in order to improve the evidence available for use in CUAs.
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objeCtives: To evaluate the quality of life (QoL) of CML patients using the EQ-5D-5L 
instrument by gathering the patient’s perspective of how, and to what extent, their 
therapy impacts QoL. Methods: Patients from the Huntsman Cancer Institute com-
CaNCeR – Patient-Reported outcomes & Patient Preference studies
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objeCtives: Examine baseline treatment patterns and persistence among patients 
diagnosed with metastatic colorectal cancer (mCRC) or Gastrointestinal stromal 
tumor (GIST) and treated with Stivarga® (regorafenib). Methods: Adult patients 
treated with Stivarga from 9/27/12-7/31/13 were identified from a large national 
US claims database. Patients were retained if they were continuously enrolled in 
the health plan for ≥ 6 months before the initial (index) fill (baseline period) and 
≥ 1 month after the index fill (follow-up period). Patients were required to be diag-
nosed with mCRC or GIST, be 18+ years old, and have non-missing demographic 
information. Follow-up persistence with Stivarga was identified based on a gap in 
therapy of at least 30 days. The use of chemotherapy in the baseline, the last regimen 
received before initiating Stivarga, and the amount of time between receipt of last 
chemotherapy and Stivarga initiation was identified. Results: 283 patients were 
treated with Stivarga and 235 met all inclusion criteria. Mean age was 61.6 years, 
66.4% were female, and 38.7% were Medicare Advantage patients. Mean baseline 
length was 4.2 years (median: 3.3 years). Mean follow-up length was 4.5 months. 
Baseline chemotherapy use was observed in 97.5% of patients; 89.5%, 72.9%, and 
79.9% of patients received irinotecan, oxaliplatin or bevacizumab, respectively. The 
most common regimens prior to Stivarga were FOLFIRI (12.7%), FOLFIRI+BEV (10.0%), 
and Irinotecan+Cetuximab (8.7%). On average, patients had a gap of 85 days from 
receipt of last chemotherapy until initiating Stivarga; 50% initiated within 30 days 
and 25% initiated after more than 84 days. Patients received 2.5 fills of Stivarga and 
were persistent for 69.5 days, on average. 37.5% of patients were persistent through 
the end of their follow-up. ConClusions: Most Stivarga-treated mCRC or GIST 
patients received chemotherapy in the 3 months prior to initiating Stivarga. At least 
half of patients were persistent for at least 8 weeks.
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objeCtives: To compare adherence rates to oral versus intravenous (IV) chemother-
apy regimens to treat metastatic colorectal cancer (CRC). Methods: A retrospective 
analysis was performed using the OptumInsight Oncology claims database. Patients 
aged 18 years and older, diagnosed with metastatic CRC between July 1, 2004 and 
December 31, 2010, who were insured by a commercial health plan were included. 
Adherence was assessed using the medication possession ratio (MPR), calculated 
as the proportion of days a patient was covered by their chemotherapy regimen, 
according to NCCN guidelines, from the first to the last cycle/prescription of that 
regimen. Comparisons of MPR between the groups were performed by multivariate 
logistic regression, using the threshold of MPR> 0.8 to define high adherence; and 
by multivariate linear regression treating MPR as a continuous variable. Results: 
A total of 9,964 chemotherapy regimens in cycles in 3,367 patients were analyzed. 
The most common regimens were IV FOLFOX (n= 1,710), oral capecitabine (n= 1,328), 
and IV FOLFOX+bevacizumab (n= 1,100). Overall, adherence was significantly higher 
for IV regimens (mean MPR = 0.88) versus capecitabine oral regimens (mean MPR 
= 0.80, p< 0.001). Additionally, a significantly higher proportion of patients receiv-
ing IV regimens (77%) achieved an MPR > 0.8 compared with patients receiving 
capecitabine chemotherapy (53%, p< 0.001). These differences persisted when 
stratifying by line of chemotherapy, age, and disease severity (measured using the 
weighted Charlson index). In multivariate logistic regression, oral chemotherapy 
regimens were associated with an odds ratio of 0.33 regarding achieving an MPR of 
> 0.8. Similarly, in multivariate linear regression capecitabine oral chemotherapy 
regimens were associated with a significant decrement in MPR (beta coefficient = 
-0.084, p< 0.001). ConClusions: Capecitabine oral chemotherapy regimens were 
associated with a significantly lower adherence rate compared with IV regimens in 
metastatic CRC patients. The clinical impact of the observed differences is unknown.
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objeCtives: The increasing availability of treatment options for metastatic breast 
cancer (mBC), particularly oral chemotherapy agents, has elevated the importance 
of adherence. This study sought to address the relationship between non-adherence 
and quality of life among women with mBC. Methods: A cross-sectional Internet 
survey was administered to 181 women diagnosed with mBC who had prior expe-
rience with either a taxane, paclitaxel, or docetaxel. Demographic, health history, 
treatment history (e.g., current use of chemotherapy [oral or IV], radiation therapy, 
or hormone therapy) and quality of life in the past 7 days (using the FACT-B) infor-
mation was collected. Patients were asked whether they had skipped/missed a 
dose and the reason for doing so (e.g., tolerability of side effects, reduce cost). The 
number of different non-adherence reasons was used to predict FACT-B scores using 
regression modeling, controlling for demographics and health history. Subgroup 
analyses were conducted among those using IV and oral chemotherapy agents, sep-
arately. Results: The mean age was 52.2 years and 93.9% were non-Hispanic white. 
42.0% and 24.3% of respondents were currently using an IV and oral chemotherapy 
agent, respectively. Across all treatments, 34.8% of respondents reported engaging 
in non-adherent behavior. Aside from hormone therapy (43.0%), non-adherence 
